|Bid||1.2700 x 1800|
|Ask||1.2800 x 900|
|Day's Range||1.2700 - 1.2900|
|52 Week Range||1.0400 - 2.0000|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for NNVC
By David Bautz, PhD AMEX:NNVC In June 2023, NanoViricides, Inc. (AMEX:NNVC) announced the initiation of a Phase 1a/b safety and efficacy clinical trial of NV-CoV-2, the company’s development candidate for the treatment of COVID-19 and other coronavirus infections. The trial is evaluating two oral formulations of the compound: NV-CoV-2 oral syrup and Nv-CoV-2 oral gummies. This is an important
Proactive research analyst John Savin speaks to Thomas Warner after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC).
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, is progressing successfully.